Welcome, Guest. Please login or register.
July 14, 2024, 12:51:45 am

Login with username, password and session length

  • Total Posts: 55130
  • Total Topics: 4851
  • Online Today: 72
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 59
Total: 59


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Tropifexor Shows Promise as Treatment for NASH  (Read 9066 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
Tropifexor Shows Promise as Treatment for NASH
« on: January 21, 2020, 11:45:26 am »
Tropifexor, a highly potent FXR agonist, led to a significant decline in weight and liver enzyme levels 12 weeks into a 48-week study among people with non-alcoholic steatohepatitis (NASH).

Arun Sanyal, MD, of Virginia Commonwealth University School of Medicine in Richmond, presented interim findings from the ongoing, randomized, double-blind, placebo-controlled Phase II FLIGHT-FXR study of tropifexor at The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Diseases, this month in Boston.

The previously reported interim results from parts A and B of the study, in which participants received between 10 and 90 micrograms of tropifexor daily, showed evidence that the drug affected the intended targets and reduced both inflammation and the level of fat in the liver without causing major changes in blood lipids.



© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.